Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 8Phase 1/2 4Phase NA 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Plasma cell 1CNS 1

Conditions

Glioblastoma 15Brain Neoplasms 15Glioma 9Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasms by Site 5Neoplasms by Histologic Type 5Hematologic Neoplasms 5Recurrence 4Neuroblastoma 4Astrocytoma 4Spinal Cord Neoplasms 3Lymphoproliferative Disorders 3Lung Neoplasms 3Colorectal Neoplasms 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma 2Laryngeal Neoplasms 2Erdheim-Chester Disease 2Central Nervous System Neoplasms 2cyclopia sequence 1Vitamin D Deficiency 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neurofibrosarcoma × CNS × Clear all
NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡